Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | METAP2 | P50579 | 3/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAT2A | P31153 | 2/20 | 0.39 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10206185 | 0.90 | CYP1A2 (0.46) | CYP1A2METAP2MDM2ALOX12KDM4E | |
| SCHEMBL15153878 | 0.86 | CYP1A2 (0.52) | CYP1A2METAP2MDM2ALOX12KDM4E | |
| SCHEMBL10449450 | 0.86 | CYP1A2 (0.52) | CYP1A2METAP2MDM2ALOX12KDM4E | |
| SCHEMBL16484319 | 0.86 | KDM4E (0.59) | CYP1A2METAP2MDM2ALOX12KDM4E | |
| SCHEMBL17228027 | 0.85 | CYP1A2 (0.51) | CYP1A2METAP2MDM2ALOX12KDM4E | |
| SCHEMBL1611068 | 0.85 | CYP1A2 (0.46) | CYP1A2METAP2MDM2ALOX12L3MBTL1 | |
| SCHEMBL10206159 | 0.84 | CYP1A2 (0.41) | CYP1A2METAP2MDM2ALOX12KDM4E | |
| SCHEMBL30118222 | 0.83 | MDM2 (0.47) | CYP1A2METAP2MDM2ALOX12KDM4E | |
| SCHEMBL1611168 | 0.83 | KDM4E (0.48) | KDM4EATML3MBTL1GSRNPSR1 | |
| SCHEMBL15749894 | 0.83 | CYP2A6 (0.48) | MDM2KDM4EMAP2K4CYP11B2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090819-B2 | Organic electroluminescent element, display device, illuminating device and condensed polycyclic heterocyclic compound | Konica Minolta, Inc. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9090819-B2 | Organic electroluminescent element, display device, illuminating device and condensed polycyclic heterocyclic compound | Konica Minolta, Inc. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20120085997-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, ILLUMINATING DEVICE AND CONDENSED POLYCYCLIC HETEROCYCLIC COMPOUND | KONICA MINOLTA HOLDINGS, INC. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120085997-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, ILLUMINATING DEVICE AND CONDENSED POLYCYCLIC HETEROCYCLIC COMPOUND | KONICA MINOLTA HOLDINGS, INC. (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120085997-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, ILLUMINATING DEVICE AND CONDENSED POLYCYCLIC HETEROCYCLIC COMPOUND | CCNE2, C1S, SCO2 | CYP1A2 643/4885METAP2 2887/4885MDM2 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.